Ivonescimab (AK112), a humanized bispecific IgG1 antibody with dual PD-1, and VEGF-binding domains, has recently shown encouraging results in early-phase clinical trials for NSCLC and other solid tumors (89, 90). This evidence concerns the gene VEGFA and non-small cell lung carcinoma.